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Abstract
Lymphatic mapping and sentinel lymph node biopsy were first reported in 1977 by Cabanas for
penile cancer. Since that time, the technique has become rapidly assimilated into clinical practice.
The sentinel node concept has been validated in cutaneous melanoma and breast cancer. However,
follow-up data of patients from randomised trials is needed to establish the clinical significance of
sentinel lymph node biopsy before accepting the procedure as a standard of care. This technique
has the potential to be utilised in all solid tumours like colon, gastric, oesophageal, lung,
gynaecologic, and head and neck cancer. This paper reviews the current status of sentinel lymph
node biopsy in solid tumours.
Background
The sentinel lymph node is defined as the first node in the
lymphatic basin into which the primary tumour drains.
Therefore, if the sentinel lymph node (SN) is not involved
with metastatic disease, the remainder of the lymph nodes
should also be negative. Likewise, if the SN is positive,
there is a risk that higher order nodes may be involved
with metastatic disease.
Cabanas [1] introduced the concept of the "sentinel node"
in 1977 when he used lymphangiograms performed via
dorsal lymphatics of the penis to demonstrate the exist-
ence of specific node or group of nodes associated with
the superficial epigastric vein that predicted the nodal sta-
tus of penile carcinoma. In 1992, Morton and colleagues
[2] described lymphatic mapping utilising an intradermal
isosulfan blue dye injection technique for malignant
melanoma and were the first to employ this concept to
localise SNs in patients with malignant melanoma. The
authors demonstrated a high success rate in identifying a
SN and in achieving low false-negative rate. In 1993, Alex
and Krag [3] introduced the use of a radioactive tracer
99mTechnetium sulphur colloid, injected intradermally
around a primary melanoma site, followed by imaging
and subsequent intraoperative use of a gamma probe to
localise and extirpate the SN. In recent years, lymphoscin-
tigraphy and blue dye have been used to trace the regional
SN in many tumours.
This simple yet revolutionary concept has raised the pos-
sibility that all solid malignancies might be amenable to
the diagnostic and potential therapeutic benefits of SN
identification and staging, and to the diminished surgical
morbidity of radical lymphadenectomy. The following
article reviews the current status of the application of SN
identification in solid malignancies.
Melanoma
The management of the regional lymphatic basin in
patients with cutaneous melanoma and no palpable
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lymphadenopathy has long been a controversial topic. No
prospective randomised trial has shown an overall sur-
vival benefit for those patients undergoing routine elec-
tive complete lymph node dissection (ELND) [4-6]. The
surgeon cannot accurately predict the nodal basin unless
the dermal tumour lies on an extremity. Even in this situ-
ation in-transit nodes might be missed in the epitrochlear
and popliteal spaces in 5% of the population [7]. This
finding raises significant concern regarding the original
randomised trials evaluating the efficacy of elective lymph
node dissection (ELND) versus observation for intermedi-
ate thickness melanomas. It is estimated that one-third of
the patients in the ELND arms had incorrect nodal basin
dissected [8-10].
With the emergence of sentinel node technology,
melanoma patients can be staged histopathologically
using lymphatic mapping and selective lymphadenec-
tomy, and spared the morbidity associated with ELND.
Studies have established that sentinel lymph node biopsy
(SNB) is safe, accurate, and reproducible when under-
taken by an experienced multidisciplinary team of profes-
sionals from nuclear medicine, surgical oncology and
pathology. Overall, the success rate of harvesting the SN
by blue dye alone is 82%, by radioactive mapping alone is
approximately 94%, and by a combination method is
98% [2,11-13]. Whether the choice of SN localisation
method, by radioactivity or blue dye is of any clinical sig-
nificance is undetermined at this time. Patients whose
sentinel nodes are tumour free require no additional
lymph node dissection. For patients whose sentinel nodes
contain metastatic melanoma, however, a complete
regional lymph node dissection is necessary. As yet, how-
ever, no prospective randomised trial has shown that this
results in a survival benefit for patients with any tumour
type compared to delay of ELND until the presence of pal-
pable nodes.
Two major studies are examining the utility of SNB in
melanoma. The Multicenter Selective Lymphadenectomy
Trial (MSLT) [14], compares wide excision and SNB to
wide excision alone in patients with clinical stage I
melanoma (localised disease). Patients with intermediate
(1–4 mm) thickness melanoma who have not had a wide
excision (with >1.5 cm margins), a skin graft, or any other
procedure that would alter the lymphatic drainage are eli-
gible. Selective completion lymph node dissection is per-
formed only when lymphatic drainage fields contain
tumour positive sentinel nodes. The purpose of this study
is to determine the therapeutic benefit of SNB and the true
accuracy of the technique at multiple international
melanoma centres. The experience from the MSLT has
shown that the combined blue dye and radiopharmaceu-
tical technique seems to work best for SNB. Patient accrual
for this trial was completed in 2002. The outcome of the
trial will determine whether SNB eventually becomes the
standard of management for patients with clinical stage I
melanoma, making conventional ELND unnecessary and
providing better outcome than the alternative 'wait and
see' approach.
A second randomised trial, the Sunbelt Melanoma Trial
[15], examines the efficacy of SNB as treatment for
tumour positive regional lymph nodes. This study com-
pares patients with one tumour positive lymph node
determined by conventional haematoxylin and eosin
(H&E) or immunohistochemical techniques (followed by
complete lymph node dissection) to observation or treat-
ment with adjuvant interferon-α. A second group of
patients who have a tumour positive sentinel by reverse
transcriptase polymerase chain reaction (RT-PCR) alone
are randomised to observation, complete lymph node dis-
section and interferon-α. The organizers of this study
anticipate that the results of this trial will provide further
insights into the therapeutic value of SNB for patients
with a single tumour positive lymph node identified by
either routine techniques or RT-PCR.
It would be ideal to determine the tumour status of the
sentinel node intraoperatively, so that subsequent
regional node dissection can be carried out immediately.
Unfortunately, frozen section examination of the sentinel
node cytology has been shown to be unreliable [16]. Sen-
tinel lymph nodes can be investigated by more extensive
pathologic evaluation. Pathologic examination of 1 or 2
lymph nodes, rather than 20 or 30, allows for a more thor-
ough and focused pathologic evaluation of the submitted
tissue. H&E is able to identify one tumour cell in a back-
ground of 10,000 normal cells; immunohistochemical
(IHC) staining identifies one tumour cell in a background
of 100,000 normal cells. Serial sectioning and IHC (with
monoclonal antibodies against HMB-45 and S-100) raise
the sensitivity some 10–20% [17]. The reverse tran-
scriptase polymerase chain reaction (RT-PCR) is an
extremely sensitive and specific technique to establish the
presence of messenger RNA from melanoma cells. RT-PCR
can detect one melanoma cell in a background of 1 mil-
lion normal lymphocytes. However, there is no data from
randomised trials on the clinical significance of
micrometastatic disease detected with IHC, serial section-
ing or even RT-PCR. It is not known whether this low bur-
den of disease can be adequately managed by the patient's
immune system, especially if the SN bearing isolated
tumour cells is removed.
Although it is tempting for the oncologic community to
assume that the SNB will alter the ultimate outcome for
patients, we must not change our management
approaches until the results of the ongoing randomised
clinical trials are available.World Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/9
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Breast
Axillary lymph node dissection (ALND) involves consid-
erable use of resources (longer surgical procedures under
general anaesthesia), and increases the risk of acute and
late morbidity that may adversely affect the patient's
health related quality of life. The complications may
include lymphoedema, pain, numbness and limited
shoulder movements [18-21]. SNB is emerging as a mini-
mally invasive alternative to axillary dissection in the stag-
ing of patients with breast carcinoma. It has the potential
to identify those patients most likely to be helped by axil-
lary dissection (i.e. those with positive nodes) and to
spare node-negative patients. The recently published
Milan trial [22] reported decreased postoperative morbid-
ity in patients undergoing SNB. However, no data exist
from randomised trials, focusing on the relapse free and
overall survival following SNB alone. Therefore, results
from randomised trials validating the sentinel node
biopsy in breast cancer are required before accepting the
procedure as the standard of care. Table 1 summarises the
ongoing randomised trials, which will resolve several
important issues.
Numerous studies have reported identification of the SN
in more than 90% of breast cancer patients, with false-
negative rates for prediction of axillary nodal status of less
than 10% [25,26]. Patient factors shown to increase the
likelihood of not finding the SN include increasing age
and body mass index [25,27,28]. No factors other than
surgeon experience have been found to influence the
false-negative rate.
The data show that there is a definite learning curve for
sentinel node biopsy that cannot be ignored [29-31]. The
ALMANAC study group has shown that standardised
training programme of in-house operative training can
decrease the learning curve [26]. The number of proce-
dures of the learning curve cannot be fixed for all sur-
geons. Until compelling evidence to suggest otherwise is
available, surgeons should perform minimum of 20 cases.
Only after documentation of a successful localisation rate
of ≥ 90% and false-negative rate of ≤ 10% should full
ALND be omitted for patients with negative sentinel
nodes. If statistical certainty is required to achieve a low
false negative rate, then Tanis et al. [32] have calculated
that over 300 cases would be required to establish a false
negative rate of <5%.
The technique of injecting the radioisotope colloid and
blue dye has been a matter of great debate. The combina-
tion technique appears to be the most accurate in identi-
fying all SNs [33]. It also appears that there is often more
than one SN. In the ALMANAC validation phase, the false
negative rate was 10.1% if a single SN was removed versus
4.9% if multiple SNs were removed. This data demon-
strates that all SNs must be removed in the initial
operation.
Table 1: Ongoing trials evaluating the role of sentinel node biopsy in breast cancer
Study[23,24] Start date Sample size Design
Axillary Lymphatic Mapping Against 
Nodal Axillary Clearance (ALMANAC)
2000 1260 Randomise to: ALND or sampling vs. SN biopsy
After Mapping of the Axilla: Radiotherapy 
or Surgery (AMAROS)
2001 3485 If SN positive randomise to: ALND vs. RT
German Clinical Interdisciplinary Sentinel 
Study (KiSS)
2000 1912 If SN negative randomise to: ALND vs. no ALND
French Randomised Sentinel Node Study 
(Fransenod)
NA* 446 SN biopsy patients randomised to peritumoural 
injection vs. periareolar injection
International Breast Cancer Study Group 
Trial (IBCSG 23-01)
2001 1960 If SN positive for micrometastases(IHC), 
randomise to: ALND vs. no ALND
American College of Surgeons Oncology 
Group (ACOSOG-Z0010)
1999 5300 IHC positive SN patients(H&E negative) observed 
to determine prognostic significance; bone 
marrow also assayed for micrometastasis to 
determine incidence and significance
American College of Surgeons Oncology 
Group (ACOSOG-Z0011)
1999 1900 If SN positive(H&E) randomise to completion 
ALND vs. observation
National Surgical Adjuvant Breast and 
Bowel Project(NSABP-B-32)
1999 4500 If SN negative randomise to: completion ALND 
vs. no additional axillary treatment
Royal Australasian College of Surgeons 
Sentinel lymph Node biopsy versus 
Axillary Clearance (RACS SNAC)
2001 1000 SN negative patients randomised to completion 
ALND vs. no additional axillary treatment
ALND, Axillary lymph node dissection; SN, sentinel lymph node; RT, radiotherapy; IHC, immunohistochemical staining; H&E, haematoxylin and 
eosin. *Not availableWorld Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/9
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The various injection techniques include intraparenchy-
mal, dermal or subdermal, and subareolar plexus. All
three techniques have been shown to be reliable in expe-
rienced hands. The dermal technique has been shown by
McMasters et al [34] to identify the SN in the axilla with
increased frequency as compared to the peritumoural
injection technique (98% vs. 90%). The dermal technique
results in significantly higher counts in the SN and com-
pares favourably with the peritumoural injection for con-
cordance and false negatives. The subareolar technique
offers many of the advantages of the dermal injection: it is
easy, it avoids the need for image guided injection and it
increases the distance of the tumour to the SN, thus elim-
inating shine through from upper outer quadrant lesions.
The transit time is also quicker than the peritumoural
technique [35]. In spite of the many advantages of the der-
mal or subareolar technique, some institutions continue
to utilise an intraparenchymal injection, because this is
the only technique that will identify internal mammary
lymph nodes. Additional questions regarding the optimal
mode of injection will be answered by the Fransenod
study (French Randomised Sentinel Node Study; Study
Chair, Dr Jean-Francois Rodier). Patients are randomised
to one of the treatment arms: 1) Patients receive peritu-
moural injections of Patent BlueV dye and technetium
Tc99m sulphur colloids 2) Patients receive periareloar
injections as in arm 1. The Fransenod trial closed in Janu-
ary 2003 after recruiting 446 patients.
Interest in evaluating internal mammary nodes (IMNs)
has recently been rejuvenated with the advent and wide-
spread acceptance of lymphatic mapping and SNB in
breast cancer. It has been established, contrary to tradi-
tional thinking, that IMN drainage is not limited to
tumours of the medial quadrant [36]. The significance of
IMN involvement is controversial, and the current prac-
tice ignores the internal mammary nodes. Most surgeons
do not intend to perform internal mammary lymph node
biopsies, even if lymphatic mapping demonstrates drain-
age to this site. Determination of IMN involvement may
alter adjuvant therapy. Fortunately, this represents only a
small number of patients as the number of instances in
which an internal mammary SN contains metastatic can-
cer when the axillary SN does not is small. Moreover,
many patients these days are receiving adjuvant therapy
based upon tumour characteristics, even if node negative
[36].
The issue of mapping for patients with a diagnosis of duc-
tal carcinoma in situ (DCIS) remains controversial. All
would agree that patients with DCIS have an excellent
long-term prognosis (98% survival). 19%–36% of
patients with DCIS on core biopsy will be found at defin-
itive surgery to have an invasive cancer [37]. More impor-
tantly, there is no way to predict preoperatively which
patients with DCIS will be upstaged to invasive cancer at
the time of definitive surgery. Lymphatic mapping is less
reliable after a lumpectomy and impossible after a mastec-
tomy. If the SNB is not performed at the time of the defin-
itive operative procedure, a significant number of patients
will be found to have an invasive cancer, which will
require a second operative procedure and in all likelihood
ALND. The majority of these patients will be found to
have a negative axilla, yet miss out on all the advantages
of SNB if not performed initially.
The role of IHC staining of the SNs also remains an area
of significant controversy. SNB and a focused pathologic
evaluation have resulted in upstaging of approximately
10%–20% of breast cancer patients. The question is
whether this detectable disease is clinically significant. All
the present literature is retrospective in nature and the
results are very inconclusive. Prospective studies are ongo-
ing to evaluate the prognostic significance of micrometas-
tases (IBCSG 23-01 trial, ACOSOG Z0010 trial) (Table 1).
Therefore, until we have good data, clinical decisions
should not be made based on inadequate studies.
The need for completion ALND in patients with a positive
SN who will receive systemic cytotoxic therapy is also con-
troversial. This important clinical question is being
addressed by the ACOSOG Z0011 trial. In this trial,
patients with a positive SN are randomised to completion
ALND or no additional axillary therapy.
Colon
As a result of the success of SNB in melanoma and breast
tumours, the technique is now being applied to other
solid tumours in the gastrointestinal tract. In breast cancer
and melanoma, most patients are found to be node nega-
tive, and avoiding radical lymphadenectomy decreases
the morbidity of the procedure. In colon cancer, the
aggressiveness of the resection is unaffected by the deci-
sion to perform a SNB, and therefore, morbidity is
unchanged. The SN theory for colorectal cancer, however,
has the potential for detecting previously unrecognised
disease and provides better nodal staging. Up to 30% of
node-negative patients with colorectal cancer develop a
recurrence and die of distant metastasis. It is postulated
that this group of patients may have occult lymph node
micrometastasis not identified at the time of colon resec-
tion and conventional pathologic evaluation. Methods
have been developed to help enhance the detection of
lymph node metastasis, including serial sectioning, IHC
staining, and RT-PCR. All of these techniques remain too
expensive and impractical to perform on all lymph nodes.
SNB aims to facilitate staging by identifying the lymph
nodes most likely to harbour metastases for thorough
pathological evaluation. It may be an efficient method of
upstaging patients at high risk for recurrence who shouldWorld Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/9
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be offered adjuvant therapy. However, the true signifi-
cance of micrometastases detected by these techniques
remains unclear.
Many reports of SNB in colorectal cancer are emerging
[38-47]. Presently, there is no standardisation; both sin-
gle- and combined-agent injection techniques have been
utilised, such as subserosal and submucosal injection, in
vivo and ex vivo injection methods, and in vivo and ex
vivo SN identification. Success rates vary from 58%–98%
of patients, with false-negative rates from 0%–60%. One
of the reasons for the difference in the false-negative rates
is the definition of false negative. If IHC staining and RT-
PCR are used, then the false-negative rate is much lower.
The mean number of SNs identified varies from a low of
one to surgeons arbitrarily choosing to count only the first
four blue lymph nodes as SNs. These results would appear
to represent a steep learning curve for a new technique.
The mapping agent should be injected near the tumour
with as little mobilisation of the colon as needed prior to
injection. When the colon is significantly mobilised and
when lymphatic mapping has been performed ex vivo,
lymphatics may be disrupted and aberrant lymphatics
might never be identified. The concordance between a
submucosal and subserosal injection is unknown. Colon-
oscopy for submucosal injection must be performed intra-
operatively or a day prior and results in colonic
distension, patient inconvenience, and increased expense.
It is not known whether single agent is better than two
agents.
Drainage to aberrant lymphatics outside the field of a
standard oncological mesenteric resection has been
reported in 0%–10% patients [40,48,49]. In some cases,
this aberrant lymph node has been found to be the only
positive lymph node. However, there is no data to support
a more extensive procedure be performed to remove SNs
outside the standard field of resection.
The results to date suggest that lymphatic mapping and
SNB in rectal cancer is not as successful as its application
in colon tumours [38,41,44,45,47]. Identification of sen-
tinel nodes below the peritoneal reflection may be diffi-
cult [49]. Also, the mesentery of the rectum should not be
disturbed until the pathologist has assessed the lateral
margins. This limits the utility of this technique for pri-
mary rectal tumours, and many surgeons are using this as
a contraindication for mapping.
SNB in colorectal cancer is still in its infancy. Prospective
randomised studies are required to determine the true sig-
nificance of micrometastases in colorectal cancer. Sentinel
node mapping may assist in this process by guiding both
surgeon and pathologist to the node most likely to har-
bour micrometastases. Should micrometastases prove to
have a prognostic impact, sentinel node mapping may
have a role to play in selecting patients for adjuvant ther-
apy. Based on the limited data at this time we cannot rec-
ommend systemic cytotoxic chemotherapy to the
upstaged patients.
Other solid cancers
A number of reports have examined the feasibility of sen-
tinel lymph node biopsy in gastric, oesophageal, lung,
gynaecologic, head and neck cancer. However, the techni-
cal aspects of the procedure remain to be perfected and
verified and the topic in general remains controversial.
Conclusion
Sentinel node biopsy is a promising new medical tech-
nique that is gaining popularity before the medical com-
munity has had time to provide adequate training and put
the procedure into practice in a safe and organised man-
ner. SNB is minimally invasive and can reduce morbidity
and cost. SNB is able to provide the pathologist with a
limited number of lymph nodes to allow a focused analy-
sis. However, the clinical relevance of tumour cells identi-
fied by immunohistochemical staining or even more
sensitive testing, such as polymerase chain reaction tech-
nology in the SN, remains unclear.
For melanoma and breast cancer, ongoing clinical trials
are in progress to determine the clinical significance of
sentinel node biopsy. Defining the role of SNB in other
malignancies remains in its infancy, but available data
suggest this approach is feasible. While the trials are
underway and outstanding questions are being answered,
surgeons should resist commercial pressure and media-
driven patient requests for performing SNB outside clini-
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